خبرين اليوم على السهم
او هذا اول خبر
DNAPrint genomics to Discuss Role of Biological Ancestry In Criminal Investigations at International Web Symposium
SARASOTA, Fla., April 13, 2005 /PRNewswire-FirstCall via COMTEX/ -- DNAPrint(TM) genomics, Inc. (OTC Bulletin Board: DNAP) announced today that the Company will make a presentation covering the role of biological ancestry in criminal investigations at the Human Identification E-Symposium International Web Conference (HumID) at 3:30 p.m. Eastern time on Thursday, April 14.
DNAPrint Forensics Technical Coordinator Zach Gaskin will specifically focus on applying the Company's DNA technology to forensics investigations.
"The worldwide HumID symposium will be an excellent forum for raising awareness among law enforcement officials for our DNAWITNESS(TM) forensics technology," said Mr. Gaskin. "DNAWITNESS(TM) is the only testing method available with predictive capabilities for identifying the percentage of a person's genetic makeup from DNA recovered at a crime scene. And because it narrows the search for potential DNA donors, it can reduce costs and the time needed to identify and question a person of interest."
Law enforcement and forensics professionals can participate in a live question-and-answer session with Mr. Gaskin and other leading industry experts by registering for the conference at
http://www.humid.e-symposium.com/speaker-program.php . All presentations and roundtable discussions at the symposium will be archived on the web site for one year. The symposium is sponsored by the Forensic Institute, based in London.
DNAPrint genomics also announced that Mr. Gaskin will discuss the science behind DNAWITNESS(TM) and case studies involving the product's application during a presentation to the Florida Homicide Investigators Association meeting in Cocoa Beach, Fla., on Friday, April 15.
The technology behind DNAWITNESS(TM) has proven useful in allowing forensics investigators to "paint" physical descriptions of a potential crime scene suspect. Using DNA samples lifted from a crime scene, DNAWITNESS(TM) can identify the percentage of a person's genetic makeup among four possible groups -- Sub-Saharan Africa, Native American, East Asian and Indo-European. The recent addition of four additional sub-groups including Northern European, Middle Eastern, Mediterranean and Indo, plus the addition of a predictive test for eye color, make this combined technology unique for criminal detective work.
Mr. Gaskin will describe how DNAWITNESS(TM) assay and associated digital photograph databases constitute a unique forensics product that has been utilized over the past two years in high profile murder cases in the United States, including the Louisiana serial killer and two California slayings -- the Concord Trail Side murder and the Mammoth Lakes murder probe. DNAWITNESS(TM) currently is being utilized in 80 other investigations worldwide.
DNAPrint genomics is continuing to make advances with its technology and recently introduced a DNAWITNESS(TM) test kit, which simplifies the process by enabling forensics experts to conduct their own tests in their own facilities without sending recovered DNA back to the Company for analysis.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company's ANCESTRYbyDNA(TM) is a consumer product for individuals interested in learning their family heritage. DNAWitness(TM) is a forensics market tool for analyzing DNA evidence recovered at a crime scene. DNAPrint is also developing products in the pharmacogenomic market including OVANOME(TM), a genomic-based diagnostic tool that matches ovarian cancer patients with the most suitable form and dose of chemotherapy, and STATINOME(TM), a test for the cardiac drug market to determine whether patients will be good or poor responders to statins, which are effective in cholesterol reduction. For more information about the company, please visit
http://www.dnaprint.com .
Safe Harbor Provision
All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.